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Introduction
The gaseous radical nitric oxide (·NO) modulates biological
function in a wide range of tissue types, acting either as a
signalling molecule or as a toxin. Cellular ·NO production is
mediated by the nitric oxide synthases (NOSs), enzymes that
use O2 and NADPH as substrates to convert the amino acid L-
arginine into L-citrulline, and release NADP+ and ·NO. Three
human NOS isoforms have been cloned and characterized.
NOS2 (sometimes referred to as inducible NOS or iNOS) is
mostly involved in the synthesis of the large amounts of ·NO
that appear in inflammatory and immunological processes
(MacMicking et al., 1997). Binding of calmodulin (CaM) to
the interdomain hinge of all NOS isoforms activates the
electron transfer from the flavins to the heme required for ·NO
production. Unlike NOS1 and NOS3, the irreversible binding
of CaM to NOS2 is essentially independent of the intracellular
Ca2+ concentrations, and it is generally assumed that CaM
binds to NOS2 co-translationally and in a 1:1 molar ratio
(MacMicking et al., 1997; Cho et al., 1992).
NOS2 was initially described in activated macrophages as an
enzyme involved in mechanisms of cytotoxicity (Hibbs et al.,
1988). This isoform is not usually expressed in healthy
quiescent cells but it is rapidly transcriptionally induced
in response to stimulation with bacterial endotoxins
[lipopolysaccharide (LPS)] or proinflammatory cytokines in
multiple cellular types. The NOS2-derived ·NO is important for
killing and host defense against certain protozoa, bacteria, fungi
and viruses (Bogdan, 2001). Although the generation of ·NO is
a feature of genuine immune-system cells (natural killer cells,
mast cells, dendritic cells, microglia, Kupffer cells, neutrophils
and eosinophils), expression of NOS2 is equally observed in
other cell types, such as epithelial cells, fibroblasts, hepatocytes
and keratinocytes, in response to various proinflammatory
stresses (Bogdan, 2001). Interestingly, although NOS2 is
usually considered in terms of physiopathological processes,
studies with NOS2 knockout mice have indicated several
physiological roles for the NOS2-generated ·NO, for example
in osteoclastic bone resorption (van’t Hof et al., 2000).
Within cells, it is not only CaM that interacts with NOS2.
Using the yeast two-hybrid approach, three more cellular
proteins that bind to NOS2 have been identified: kalirin,
NAP110 (both binding to the first 70 amino acids of NOS2)
and Rac (binding to the oxygenase domain) (Ratovitski et al.,
1999a; Ratovitski et al., 1999b; Kuncewicz et al., 2001).
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Several cell types express inducible nitric oxide synthase
(NOS2) in response to exogenous insults such as bacterial
lipopolysaccharide (LPS) or proinflammatory cytokines.
For instance, muscular cells treated with LPS and
interferon g (IFN-g ) respond by increasing the mRNA and
protein levels of NOS2, and synthesize large amounts of
nitric oxide. We show here that transcriptional induction
of NOS2 in muscular cells proceeds with a concomitant
decrease in the levels of caveolin-1, -2 and -3. Addition of
·NO-releasing compounds to C2C12 muscle cells reveals
that this downregulation of the caveolin (cav) levels is due
to the presence of ·NO itself in the case of caveolin-3 and to
the action of the LPS/IFN-g in the case of cav-1 and cav-2.
Likewise, muscle cells obtained from NOS2–/– knockout
mice challenged with LPS/IFN-g could downregulate their
levels of cav-1 but not of cav-3, unlike wild-type animals, in
which both cav-1 and cav-3 levels diminished in the
presence of the proinflammatory insult. Laser confocal
immunofluorescence analysis proves that ·NO exerts
autocrine and paracrine actions, hence diminishing the
cav-3 levels. When the induced NOS2 was purified using an
affinity resin or immunoprecipitated from muscular
tissues, it appears strongly bound not only to calmodulin
but also to cav-1, and marginally to cav-2 and cav-3.
When the cav levels where reduced using antisense
oligonucleotides, an increase in the NOS2-derived ·NO
levels could be measured, demonstrating the inhibitory role
of the three cav isoforms. Our results show that cells
expressing NOS2 diminish their cav levels when the
synthesis of ·NO is required.
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Kalirin is a cytosolic protein with nine spectrin-like repeats
that inhibits NOS2 by preventing the formation of the
active homodimers (Ratovitski et al., 1999a). NAP110 is a
membrane-bound macrophage protein that also promotes the
dimer-to-monomer conversion of NOS2, resulting in the loss
of enzymatic activity (Ratovitski et al., 1999b). Finally, Rac, a
member of the Rho GTPase family, binds to NOS2 and, upon
overexpression, slightly increases the enzymatic synthesis of
·NO (Kuncewicz et al., 2001).
Interaction of NOS1, NOS2 and NOS3 with some of the
three caveolin (cav) isoforms has also been reported. In this
context, the process involving the interaction of cav-1 with
NOS3 (eNOS) is undoubtedly the best characterized. Reports
from the laboratories of Michel and Sessa have established a
model in which, in endothelial cells, myristoylated and doubly
palmitoylated NOS3 translocates from the cytosol towards
low-fluidity subdomains enriched in cav-1. As a consequence
of this new localization, a direct inhibitory interaction between
NOS3 and cav-1 residues 82-101 occurs that ultimately
discontinues the ·NO synthesis. Because this process takes
place when the intracellular calcium concentration is low, CaM
is released from the hinge region that connects both domains
of NOS3. This model also envisages a self-excluding
regulatory cycle between cav-1 and CaM when binding to
NOS3. When the intracellular calcium concentration increases,
NOS3 becomes de-palmitoylated, cav-1 is released and CaM
binds again (Gratton et al., 2000; Feron et al., 1998).
However, less is known about the interaction of NOS2 with
caveolin isoforms, despite the fact that they are abundantly
expressed in cell types in which NOS2 is expressed in response
to inflammatory stimuli. Additionally, it is not clear whether
certain post-translational modifications occur on NOS2 that
favor its redistribution to membranous subdomains, where the
interaction with caveolin might take place. For instance, in Raw
264.7 macrophages, antibodies raised against the first 17 amino
acids of NOS2 were able to react with a cytosolic but not with
a membrane-bound form of NOS2, whereas antibodies that
recognize the C-terminus of NOS2 recognized both the soluble
and membrane-associated NOS2 (Ringheim and Pan, 1995).
Significantly, primary cultures of activated mouse macrophages
also displayed a subpopulation of NOS2 that remained
membrane-bound (Vodovotz et al., 1995) and in slow-twitch
fibers of guinea-pig skeletal muscle NOS2 immunoreactivity
was found almost exclusively in the particulate fraction (Gath
et al., 1996). However, it remains to be established whether
the membrane-bound subpopulation of NOS2 associates with
caveolin and whether this interaction leads to its enzymatic
inhibition. In this regard, a recent report has described that the
ectopic expression of cav-1 in carcinoma cell lines results in the
translocation of NOS2 to Triton-X-100-insoluble subdomains
termed caveolae, where it becomes degraded via the proteasome
pathway (Felley-Bosco et al., 2000). The possibility therefore
exists that cav-1 interacts with NOS2 and regulates its activity.
In agreement with this observation, incubation of purified
NOS2 with the ‘scaffolding domain’ peptide of both cav-1
(residues 82-101) and cav-3 (residues 55-74) completely
abrogated ·NO synthesis by NOS2 (García-Cardena et al.,
1997). Hence, the intriguing possibility of CaM-bound NOS2
physiologically interacting with and being regulated by cav-1
in a ternary complex remains unexplored.
In this work, we have primarily focused on skeletal muscle
cells, because they represent a well-established model of NOS2
induction in response to proinflammatory stimuli. Although
NOS2 is expressed at low levels in normal human skeletal
muscle (Park et al., 1996; Tews et al., 1998), its gene
expression is significantly increased in patients with severe
or chronic heart failure (Riede et al., 1998). Although both
immunohistochemistry (Gath et al., 1999) and immunogold
labeling (Adams et al., 1999) localized NOS2 predominantly
over the myofibrils of skeletal muscle, other reports
unambiguously localize NOS2 only at the sarcolemma (the
plasma membrane of the muscle cell) (Tews et al., 1998).
Additionally, in C2C12 skeletal muscle cells, NOS2
immunoprecipitates with the sarcolemmal membrane protein
cav-3 (Gath et al., 1999), probably providing a molecular basis
for the localization of NOS2 to the sarcolemma of muscle
cells observed in certain studies. Here, we report that
proinflammatory stimuli induce the appearance of NOS2 in
muscle cells with a concomitant decrease in the caveolin
levels, probably allowing the enzyme to reach full activity.
Furthermore, the released ·NO acts in an autocrine and
paracrine fashion, and diminishes the amount of the cav-3 that
is present in neighboring cells.
Materials and Methods
Cell culture and materials
Glutamine, antibiotics, cell culture media [Dulbecco’s modified Eagle
medium (DMEM)], sulfanilic acid (4-amino-benzenesulfonic acid),
NEDA [N-(1-naphthyl) ethylenediamine dihydrochloride], nitro-
arginine, LPS (from Salmonella enteriditis), transfection reagents
Escort-III and Escort-IV, 2¢ ,5¢ -ADP (adenylic acid) and Hoechst 3342
were purchased from Sigma. Trypsin-EDTA and fetal bovine serum
(FBS) were from Bio Whittaker Europe. The sources of the various
antibodies used in this work are: anti-NOS2 polyclonal serum
(N32030), anti-cav-1 polyclonal serum (C13630), anti-cav-1
monoclonals (clone 2234 and 060), anti-cav-2 monoclonal (clone 65)
and anti-cav-3 monoclonal (clone 26) were from Transduction
Laboratories; anti-b -tubulin-I (T7816) monoclonal antibody, anti-
CaM monoclonal antibody (clone 6D4) and anti-NOS2 monoclonal
antibody (N9657) were purchased from Sigma. Recombinant
human interferon g (IFN-g ) was from PeproTech. DETA
NONOate {[Z]-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]
diazen-1-ium-1,2-diolate} and 1400W dihydrochloride {N-[3-
(aminomethyl)benzyl]acetamidine} were from Cayman Chemicals.
Protein-A/Sepharose, 2¢ ,5¢ -ADP/Sepharose, ECL reagents, Cy2-
and Cy3-labelled secondary antibodies were from Amersham
Biosciences. Antisense phosphorothioates were from Sigma-Genosys.
NOS2 knockout mice (B6.129P2 and C57BL/6J000664 control strain)
were obtained from Jackson Laboratories (Bar Harbor, ME). The
protein kinase inhibitors were obtained from Calbiochem. BODIPY
Texas Red ceramide was from Molecular Probes.
C2C12 mouse myoblasts were kindly provided by M. Lorenzo
(Universidad Complutense de Madrid). The myoblasts were grown in
DMEM supplemented with 10% FBS, 100 U ml–1 penicillin, 100 m g
ml–1 streptomycin and 2 mM L-glutamine in a 5% CO2 atmosphere
at 37°C. Differentiation of ~70% confluent myoblasts into myotubes
was performed in DMEM supplemented with antibiotics and
glutamine plus 50 nM insulin in the absence of serum for 3 days
(Conejo et al., 2001). Myotubes (muscular cells) are characterized by
the formation of elongated, multinucleated tubules that express cav-
3. After the formation of the myotubes, the cells were incubated
overnight with DMEM in the presence of 10% serum before adding
the LPS/IFN-g . To induce NOS2 expression in C2C12 myotubes, LPS
(2 m g ml–1) plus IFN-g (100 U ml–1) was added in the presence of
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DMEM and 10% FBS. The supernatant and the cells were collected
at different times and analysed.
Determination of the ·NO release
Because nitric oxide decomposes to nitrites and nitrates, we determined
the concentration of nitrites in the samples using the Griess assay. A
0.5 ml sample was incubated with 50 m l of a 100 mM sulfanilic acid
solution and 50 m l of a 10 mM NEDA solution. The mixture was
allowed to react for 15 minutes and then the absorbance value at 540
nm was determined. Every sample was analyzed in triplicate. Fresh
solutions of sodium nitrite were regularly prepared as standards.
Depletion of endogenous cav-1, cav-2 and cav-3 using
antisense phosphorothioates
We designed three 21-bp antisense phosphorothioates that annealed
starting at the first ATG codon (initiation Met) of the cav-1, cav-2 and
cav-3 mRNAs. Antisense phosphorothioate oligonucleotides (7.5 m M)
were transfected into C2C12 myotubes using Escort transfection
reagent (Sigma) for 8 hours in DMEM in the absence of serum.
Afterwards, the transfection mixture was removed, the cells were
washed with DMEM with 10% FBS and the myotubes were
challenged with LPS/IFN-g for 36 hours. After this, the medium was
collected and the ·NO synthesis was determined using the Griess
assay. Likewise, the cells were scraped and harvested in order
to immunodetect caveolin levels within them. Because the
oligonucleotides tended to precipitate during the transfection process,
resulting in variable transfection efficiencies, ten independent
experiments of endogenous caveolin depletion were performed.
Construction of the NOS2-GFP plasmid
We PCR amplified the NOS2 cDNA (original clone from C. Nathan,
Weill Medical College of Cornell University, New York) introducing
a novel NcoI site at the 5¢ end and a novel BssHII site at the 3¢ end.
The general design of the mutant consisted of NOS2 cDNA fused to
the enhanced green fluorescent protein (GFP) using a BssHII site
in the pCDNA3 plasmid (Invitrogen) under the control of the
cytomegalovirus promoter, as previously described (Navarro-Lérida et
al., 2002). The PCR-amplified band was then ligated into the pGEM-
T vector (Invitrogen) and subsequently sequenced. We then double
digested the NOS2 in pGEM-T with NcoI plus BssHII and ligated this
band into the corresponding sites of a pUC-linker-GFP construct that
we had previously obtained (Navarro-Lérida et al., 2002). In this
construct, we had a BssHII at the 5¢ end of the GFP coding region, as
well as a XhoI at the 3¢ end followed by a hexa-His ending with a XbaI
site. This NOS2-GFP pUC construct was digested with XbaI for 2
hours and EcoRI was then added for 5 minutes in order to induce a
partial digestion (there are internal EcoRI sites within the NOS2
cDNA). Finally, the larger band obtained from this partial digestion
(~4.2 kb) was ligated into pCDNA3 that had been previously digested
with EcoRI plus XbaI. This NOS2-GFP pCDNA3 plasmid was used
to transfect myoblasts and myocytes in culture using Escort-III and
Escort-IV (Sigma) following the manufacturer’s instructions.
Induction of NOS2 expression in wild-type and knockout mice
Mice were injected intraperitoneally with LPS (1.5 m g LPS g–1) and
IFN-g (8 U g–1). PBS was injected into control animals in every
experiment. After 16 hours, the animals were sedated, sacrificed and
an extract of muscle (quadriceps) and liver obtained. A minimum of
four mice were used in every condition.
Inhibition of cellular protein kinases
C2C12 myotubes were incubated with LPS/IFN- g in the presence of
various protein kinase inhibitors. We tested wortmannin (200 nM), LY
294002 (20 m M), SB 203580 (5 m M), PD 98059 (10 m M) and
genistein (10 m M). 36 hours after the activation, both the supernatant
and the cells were harvested and the levels of cav-1 and cav-2
determined by immunoblotting. The concentration of nitrites in the
supernatant was determined using the Griess assay as previously
described.
Immunoblot analysis and cellular fractionation
Cellular proteins were resolved by either 7% or 15% acrylamide
sodium-dodecyl-sulfate polyacrylamide-gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes. Western blots
were incubated for 2 hours in PBS containing 2% powdered skim
milk. Subsequently, the nitrocellulose membranes were incubated
overnight with the primary antibodies (typically 1:1000 in PBS),
washed and finally incubated for 2 hours with a horseradish-
peroxidase-conjugated goat anti-rabbit antibody (Pierce).
Detection was performed using an ECL detection kit (Amersham
Biosciences). Quantification of the intensity of the bands was
performed using the UViband V97 software (UVItec St John’s
Innovation Centre, Cambridge, UK).
Fractionation was performed by harvesting the C2C12 myotubes
treated with LPS/IFN-g for 36 hours and resuspending them in 0.4 ml
PBS supplemented with 1 mM EDTA, 10 m g ml–1 aprotinin, 10 m g
ml–1 leupeptin, 2 m M phenylmethylsulfonyl fluoride (Sigma) as
protease inhibitors. The cellular suspensions were then passed several
times through a syringe (0.5 · 16 mm) on ice. Unbroken cells and
cellular debris were eliminated by a 10-minute centrifugation at 5000
rpm in a tabletop microcentrifuge. The samples were then centrifuged
for 1 hour at 200,000 g in an SW65 rotor (Beckman) at 4°C as
previously described (Navarro-Lérida et al., 2002). The cellular
pellets (particulate fraction) and the supernatants (soluble fraction)
were brought to equal volumes and subsequently analysed by SDS-
PAGE followed by immunodetection with the indicated antibodies.
Immunoprecipitation and purification of NOS2 from muscle
C2C12 myotubes treated for 36 hours with LPS/IFN- g were washed
with PBS, scrapped and lysed in Ripa buffer (10 mM Tris, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS, 0.1% deoxycholate, pH 7.35) in
the presence of protease inhibitors. After centrifugation of the cell
lysate at 6000 g for 10 minutes at 4°C, the supernatant was precleared
with 20 m l of Sepharose:Protein-A/Sepharose beads (Amersham
Biosciences) in the absence of any added antibody for 1 hour at 4°C.
The sample was spun and the beads removed. Afterwards, 5 m l of
the rabbit anti-NOS2 antibody were added to the sample and the
mixture was incubated overnight at 4°C. Then, 25 m l of a 1:1
Sepharose:Protein-A/Sepharose suspension were added to each
sample and the incubation was maintained for 5 hours at 4°C.
Immunoprecipitates were centrifuged at 15,000 rpm in a tabletop
microcentrifuge for 10 minutes and the supernatant was removed.
Samples were washed once with PBS to remove non-specific
interactions, spun again and separated by SDS-PAGE, transferred to
a membrane and immunodetected with the desired antibody.
NOS2 was purified using 40 plates of confluent C2C12 myotubes
treated with LPS/IFN-g for 36 hours as the starting material by means
of a 2 ¢ ,5¢ -ADP/Sepharose affinity chromatography. The purification
steps are similar to those previously reported (Rodriguez-Crespo et
al., 1999) with the sole exception that the elution from the affinity
column was performed with 25 mM 2 ¢ ,5¢ -ADP. The purified NOS2
was extensively dialysed against 100 mM (NH4)HCO3, pH 8.5, and
then lyophilized.
Confocal fluorescence microscopy
Cells grown on 0.2% gelatin-coated glass coverslips were washed two
1690
times with PBS and fixed for 15 minutes at room temperature with
freshly prepared 2% paraformaldehyde in PBS. The stock
paraformaldehyde solution was prepared at 4% in PBS and was
centrifuged at 15,000 rpm for 5 minutes at room temperature in a
table-top microcentrifuge in order to remove insoluble material before
dilution. After removal of the 2% paraformaldehyde solution, the cells
were washed with PBS and incubated with cold methanol at –20°C
for 10 additional minutes. The methanol was removed and the
coverslips were allowed to dry for 5 minutes. Then, the cells were
washed with PBS and incubated with the desired primary antibodies
at 37°C. In general, an overnight incubation was performed with the
primary antibodies at a 1:200 dilution in a wet chamber followed by
a 2 hour incubation with the secondary antibody. Finally, the slides
were mounted using Fluoroguard anti-fade reagent (BioRad). The
subcellular localization was observed under a BioRad Radiance 2100
confocal microscope, using the excitation wavelength of 405 nm for
the Hoechst fluorescence (nuclear staining), 488 nm for the Cy2
fluorescence and 543 nm for the Cy3 fluorophore. A 60 · oil-
immersion objective was used. Analysis of the pictures was performed
with the Confocal Assistant software (free software by T. Clark,
version 4.02, http://www.cyto.purdue.edu) as well as with Laserpix
and Lasersharp software from BioRad. Treatment of live cells with
the Golgi marker BODIPY-Texas Red ceramide was performed as
previously described (Navarro-Lérida et al., 2002).
Results
Proinflammatory stimuli upregulate NOS2 and
downregulate caveolin levels in muscle cells
Mouse C2C12 myotubes are known to induce NOS2
transcriptionally in response to bacterial LPS and IFN-g , so we
first determined whether these stimuli could also affect the
caveolin levels (Fig. 1). A low level of NOS2 can be observed
in myotubes under basal conditions. As expected, addition of
2 m g ml–1 LPS plus 100 U ml–1 IFN-g to mouse C2C12
myotubes results in the transcriptional induction of NOS2 with
the consequent synthesis of large amounts of ·NO that
accumulate in the culture medium. The amount of NOS2 that
can be immunodetected in C2C12 myotubes steadily increases
up to 30 hours of treatment, and the released ·NO (measured
as accumulated nitrites) follows a similar pattern (Fig. 1A).
However, when we determined the levels of cav-1, cav-2
and cav-3 that were present in myotubes under these
circumstances, we observed a progressive diminution of the
protein levels of all of them (Fig. 1B). The cav-1 protein
(continuous line in Fig. 1B) becomes downregulated promptly,
reaching about 55% of the initial levels after 24 hours of
treatment with the cytokines, and about 28% of the initial levels
after 48 hours of treatment. The cav-2 protein levels diminish
as well (dotted line), with half of the total cellular protein levels
being lost after 48 hours of treatment. Reduction in cav-3, the
muscle-specific isoform, is equally observed (dashed line),
although somehow more retarded with time. After 48 hours of
incubation with LPS/IFN-g , 65% of the initial protein content
of cav-3 is still present, falling down to 37% after 56 hours of
treatment. Hence, when the C2C12 myotubes transcriptionally
increase their NOS2 levels, a concomitant decrease in the
caveolin levels are observed.
Subcellular localization of NOS2 and cav-1, cav-2 and
cav-3 in C2C12 myotubes
Next, we decided to investigate the intracellular distribution of
NOS2 and its putative overlap with the caveolin isoforms
(Fig. 2). In untreated myotubes, cav-1, cav-2 and cav-3
strongly label the sarcolemma (plasma membrane), although,
in agreement with previous observations (Luetterforst et al.,
1999), it also localizes to intracellular membranes, most likely
the Golgi apparatus (Fig. 2A, left). No nuclear distribution
of caveolin was observed in any case. In the absence
of proinflammatory stimuli, the amount of NOS2
immunodetected in C2C12 myotubes is very low, almost non-
existent (Fig. 2A, middle). Upon treatment of these cells with
LPS/IFN- g for 36 hours, a clear cytosolic NOS2 staining could
be observed (Fig. 2B). The caveolin staining becomes not only
reduced but also non-uniform along any microscope field, and
the overlap between NOS2 and caveolin-1 is found mostly
in intracellular membranes within the sarcoplasm (yellow
staining). The intracellular localization of NOS2 extends
throughout the cytoplasm and becomes extinguished in the
proximity of the sarcolemma. Overlap of cav-2 and NOS2 is
less obvious than in the case of cav-1, whereas no overlap
between cav-3 and NOS2 could be observed in stimulated cells
(Fig. 2B). Detailed observation of the NOS2 distribution with
a higher magnification reveals that, in certain subcellular
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Fig. 1. Induction of NOS2 proceeds with the concomitant
downregulation of the cav-1, cav-2 and cav-3 levels in mouse C2C12
myotubes treated with LPS/IFN-g . Myotubes were treated with
LPS/IFN- g and the changes in NOS2, cav-1, cav-2 and cav-3 were
analysed by immunoblot and quantified using the UVI-band
software. Induction of NOS2 together with the accumulation of
nitrites is depicted in (A) The intensity of the NOS2 bands at five
different times as integrated using the UVI-band software is shown at
the top. Accumulated nitrites in a 54 hour period is shown at the
bottom. The disappearance of cav-1 (continuous line), cav-2 (dotted
line) and cav-3 (dashed line) in myotubes is represented in (B), both
as the immunodetected bands (top) and as a plot (bottom). Protein
levels are expressed as percentage of the maximum; the initial
amount of caveolin is therefore 100%. b -Tubulin is also shown as a
control of total protein in each sample. The results shown are
representative of four experiments (means±s.d.).
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structures, it is not evenly distributed but instead repeatedly
constitutes aggregated structures (see below). In the cells that
simultaneously express NOS2 and caveolin, colocalization can
be observed in certain membranous structures of the cytosol.
Other activated cells limit their caveolin staining to the
sarcolemma, with NOS2 being found all over the sarcoplasm.
It is likewise remarkable that any
myotube that rapidly responds to
the proinflammatory cytokines and
induces NOS2 expression eventually
downregulates the levels of caveolin,
specifically suggesting that NOS2 and
caveolin expression are mutually exclusive
at long times. This seems to be a common
phenomenon for all cav-1, cav-2 and cav-
3. Still, certain individual cells seem not to
respond to the LPS/IFN- g stimulus. Hence,
even after 48 hours of treatment, certain
cells in the culture (approximately 15% of
the total) seem not to respond to the
stimuli.
Because the amount of cav-1, cav-2 and
cav-3 decrease in C2C12 myotubes after
treatment with the mixture of LPS and
IFN-g , we investigated the distribution
of NOS2 under situations of abundant
caveolin presence (Fig. 3). Myoblasts were
stained with the Golgi marker BODIPY
Texas red ceramide in vivo, as previously
reported (Navarro-Lérida et al., 2002). A
very significant co-localization of NOS2
and BODIPY Texas red ceramide was
apparent in perinuclear Golgi regions of
the cell (Fig. 3A), which are probably
enriched in caveolin (Luetterforst et al.,
1999; Navarro-Lérida et al., 2002).
Transfection of myoblasts and myotubes with the reporter GFP
plasmid resulted in the distribution of the fluorescence in the
cytosol and the cell nucleus (Fig. 3B, left). However, the
distribution of a NOS2-GFP construct in both myoblasts and
unactivated myotubes is punctate in perinuclear areas and in
the sarcolemma, clearly indicating that, when caveolin is
Fig. 2. Subcellular localization of NOS2 and
the various caveolin isoforms in mouse C2C12
myotubes in control experiments (A) and in
cells treated with the proinflammatory mixture
of LPS/IFN-b (B). (Left) Myotubes were fixed
with paraformaldehyde and methanol, and
incubated with antibodies against cav-1, cav-2,
cav-3 or NOS2 and either left untreated (A) or
treated with LPS/IFN-g for 36 hours (B).
(Middle) Subcellular distribution of NOS2 in
myotubes untreated (A) or treated with
LPS/IFN- g for 36 hours (B). The merge signal
is depicted on the right. The caveolin
fluorescence was visualized by confocal
microscopy at an excitation wavelength of 488
nm and is shown in green, whereas the NOS2
was obtained after excitation at 543 nm and is
shown in red. Overlap of green and red
labeling is depicted in yellow; overlap of green
and blue labeling is depicted in light blue;
overlap of red and blue is depicted in violet.
Scale bar, 50 m M. In all cases, the position of
the cell nuclei (blue) was obtained after
staining with Hoechst and excitation at
405 nm.
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abundant, NOS2 associates preferentially with intracellular
membranes (Fig. 3B, middle). This particulate staining of
NOS2 is more apparent at a higher magnification (Fig. 3B,
right).
Effect of a ·NO donor on the caveolin levels in C2C12
myotubes
We intended to determine whether the diminution in the
caveolin levels observed in the presence of the inflammatory
insult were due to a transcriptional downregulation process
induced by the LPS or IFN- g themselves, or, alternatively, to
the ·NO released by the activated myotubes. Remarkably,
incubation of C2C12 myotubes with LPS/IFN- g in the presence
of the NOS2 inhibitors 1400W and nitro-Arg led to the
downregulation of cav-1 and cav-2, and, at the same time,
abrogated the expected diminution in the cav-3 levels (Fig.
4A). Moreover, addition of DETA-NONOate, a nitric-oxide-
releasing compound, downregulates cav-3 but not cav-1 and
cav-2. The possibility therefore exists that the decrease in the
immunodetected cav-3 is the consequence of a transcriptional
or transductional downregulation triggered by
nitric oxide itself. Treatment of myocytes with
LPS/IFN- g plus DETA-NONOate resulted in
lower levels of cav-3 (Fig. 4A). The data
suggest that the decrease in the cav-1 and cav-
2 protein levels is due to the cytokines,
whereas the decrease in the cav-3 protein
levels is due to the ·NO resulting from NOS2
activity. Interestingly, this observation
rationalizes our previous finding that cav-3
downregulation is somehow delayed
compared with cav-1 and cav-2 (Fig. 1B). In
order to gain further insight into the
mechanism exerted by ·NO on the
downregulation of the cav-3 protein content,
C2C12 myotubes were incubated with 20 m M
8-bromo-cGMP, a cell-permeable analog of
cGMP (Fig. 4B). In the presence of neither 8-
bromo-cGMP nor ODQ (a well-known
inhibitor of soluble guanylate cyclase) could
we observe changes in the cav-1 and cav-2 levels (data not
shown). Remarkably, the cav-3 protein levels were very
marginally affected by this treatment, ruling out the ·NO-
cGMP signaling pathway as the only mechanism leading to the
downregulation that we previously observed. In addition,
neither ODQ nor cycloheximide (CHX) were able to abrogate
the downregulation of cav-3 observed in the presence of the
·NO donor DETA-NONOate (Fig. 4B). Likewise, ODQ alone
induced no changes in the cav-3 levels (data not shown). In
conclusion, the downregulation of the cav-3 by ·NO does not
proceed through cGMP-derived pathways and does not seem
to require de novo cellular synthesis of proteins.
Physical association between NOS2 and the three
caveolin isoforms
Next, we attempted to investigate the interaction of cav-1,
cav-2 and cav-3 with NOS2 in myotubes both by
immunoprecipitation and through the purification of NOS2
using an affinity column (Fig. 5). When an extract from
activated C2C12 myotubes is fractionated into soluble and
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Fig. 3. Localization of NOS2-GFP to the Golgi
apparatus (A) and particulate immunofluorescence
of NOS2-GFP both in myoblasts and myotubes
(B). Live C2C12 myoblasts were grown on glass
coverslips, transfected with a NOS2-GFP
construct and incubated with the Golgi marker
BODIPY-Texas red ceramide (A). In addition,
C2C12 myoblasts and myotubes were grown on
glass coverslips and transfected with GFP alone
(left) or with a construct of NOS2 fused to the
GFP reporter (right) (B). (B, far right)
Magnification of myotubes transfected with a
NOS2-GFP construct. The subcellular localization
was analysed by laser confocal microscopy at an
excitation wavelength of 488 nm. Scale bar,
10 m M (bottom), 50 m M (all others). In all cases,
the position of the cell nuclei (blue) was obtained
after staining with Hoechst and excitation at
405 nm.
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membranous fractions, approximately 80% of the NOS2
immunoreactivity remains in the soluble cytosolic fraction and
about 20% remains associated with membranes (Fig. 5A).
Interestingly, the membrane-associated NOS2 migrates with a
slightly larger molecular mass than the soluble, cytosolic
NOS2. We are currently exploring the putative post-
translational modifications present in the inducible NOS in
C2C12 muscle cells. As expected, cav-1, cav-2 and cav-3 all
associate with the particulate fraction of the cell (Fig. 5A).
Immunoprecipitation of NOS2 from activated muscle cells was
performed with a polyclonal serum (Fig. 5B). The enzyme
appears to be associated strongly with cav-1 and CaM, and, to
a lesser extent, with cav-2 and cav-3. Because NOS2 binds
irreversibly to CaM, this finding indicates that, unlike
endothelial NOS3, NOS2 can simultaneously associate with
calmodulin and with caveolin, and preferentially with cav-1. In
order to approximate the stoichiometry of this interaction we
purified NOS2 by affinity chromatography on a 2¢ ,5¢ -
ADP/Sepharose resin. Next, we loaded the appropriate
amounts of both purified NOS2 and of a total lysate of activated
C2C12 myotubes so that a similar band of NOS2 would be
immunodetected (Fig. 5C). As observed in Fig. 5, cav-1, cav-
2 and cav-3 purified with NOS2, although to very different
extents. For instance, a significant amount of the total cellular
cav-1 interacts with NOS2, whereas only minimal amounts of
cav-2 and cav-3 associate with NOS2. The presence of more
cav-1, but not cav-2 or cav-3, in association with NOS2 argues
for a preferential interaction with this isoform. Support for a
specific interaction with cav-1 is provided by the fact that
significant amounts of cav-2 and cav-3 can still be
immunodetected in the cellular lysate. These results establish
that, although the three isoforms of caveolin associate with
NOS2, there is a preferential binding to cav-1.
Depletion of caveolin using antisense oligonucleotides
and effect of protein kinase inhibitors
In order to prove that the caveolin present within muscular cells
associate with NOS2, hence reducing its enzymatic activity, we
transfected C2C12 myotubes with antisense oligonucleotides for
8 hours. After this treatment, the culture medium was replaced
and the cells were confronted with the proinflammatory stimulus
for 36 hours. Nitrites that accumulated in the medium of mock
and LPS/IFN-g -treated cells were then determined (Fig. 6).
Depletion of the endogenous cav-1 and cav-2 levels increased
the amount of the ·NO synthesized by approximately 52% and
50%, respectively, whereas depletion of endogenous cav-3
resulted in an increase in 24%. Addition of a mixture of the three
antisense oligonucleotides resulted in an increase in 50% in the
·NO synthesis. No changes were observed in the levels of NOS2
or b -tubulin as a consequence of the treatment. Immunoblotting
analysis of the amount of cav-1, cav-2 and cav-3 protein
resulting from the phosphorothioate treatment reveals that the
C2C12 myotubes possess, in all cases, 60-70% of the caveolin
protein content observed in untreated cells. Still, we cannot rule
out the possiblity that, after 24 hours of incubation with
LPS/IFN-g in the absence of antisense oligonucleotides, the cells
partially recover from the treatment and increase their content in
cav-1, cav-2 and cav-3. It must be noted that incubation with the
antisense oligonucleotides specific for cav-1 frequently affected
not only the cav-1 protein levels but also the cav-2 levels and
vice versa, in agreement with the known hetero-association
formed between cav-1 and cav-2 within cells. Thus, in
accordance with the proposed role of caveolins as inhibitors
of the activity of NOSs, reduction in the cav-1, cav-2 and
(marginally) cav-3 levels proceeded with the concomitant
increase in ·NO synthesis.
Next, we activated the C2C12 myotubes with LPS/IFN-g and
tried to determine whether the downregulation in the cav-1 and
Fig. 4. Treatment of myotubes with ·NO donors induce changes in
the levels of cav-3, but not of cav-1 or cav-2. C2C12 myoblasts were
differentiated into myotubes and incubated with LPS (2 m g ml–1)
plus IFN-g (100 U ml–1), the ·NO donor DETA-NONOate (100 m M),
the ·NO inhibitors 1400W (100 m M) and nitro-Arg (100 m M) for 36
h (cav-1 and cav-2) or 48 h (cav-3) in different combinations. The
cells were scraped and the changes in cav-1 (white bars), cav-2
(single-slashed bars) and cav-3 (double-slashed bars) protein levels
were determined by immunodetection (A). In addition, activated
C2C12 myotubes were incubated with the ·NO donor DETA
NONOate, the lipophilic cGMP analog 8-bromo-cGMP (20 m M),
with the soluble guanylate cyclase inhibitor ODQ (10 m M) or with
cycloheximide (CHX; 10 m M) in various combinations for 48 hours,
and the levels of cav-3 were determined by immunodetection (B). In
every case, the total amount of protein loaded was similar, as judged
by b -tubulin quantification. *P<0.001 vs the corresponding condition
in the absence of ·NO donor. Averaged results are shown, being
representative of at least three independent experiments (±s.d.).
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cav-2 levels could be blocked in the presence of protein kinase
inhibitors (Fig. 6B). When the LPS/IFN-g mixture was present,
the cav-1 levels diminished to 40% of the initial protein levels,
although this decrease could be partially abrogated in the
presence of PD 98059, an inhibitor of the ERK pathway. By
contrast, the C2C12 myotubes incubated with the LPS/IFN-g
mixture and challenged with none of wortmannin, LY 294002,
SB 203580 and genistein could sustain the cav-1 protein levels
observed in the control sample. Similar behavior was obtained
when the cav-2 levels were determined. (data not shown). With
this result in mind, we determined the concentration of nitrites
that was present when PD 98059 was added to the cell culture
(Fig. 6B). As expected, the restoration of the immunodetected
cav-1 protein levels in myotubes in the presence of the LPS/IFN-
g mixture plus PD 98059 had produced a clear diminishment in
the NOS2-derived ·NO (Fig. 6B, right). Hence, the sustained
cav-1 and cav-2 levels even in the presence of the LPS/IFN-g
mixture are responsible for the abrogated activity of NOS2. It
must be noted, nevertheless, that the addition of PD 98059 did
not induce significant alterations in the NOS2 protein levels that
were induced in the presence of the cytokines (data not shown).
Changes in the muscle caveolin levels in wild-type and
NOS2 knockout animals
To explore the behavior of muscle cells in live animals and
complement our studies carried out in cell cultures, we injected
LPS and IFN-g into both wild-type and NOS2
knockout mice (Fig. 7). After 36 hours of treatment,
both the NOS2+/+ and the NOS2–/– animals
effectively diminished their cav-1 protein levels
immunodetected in skeletal muscle extracts. The
wild-type animals downregulated their cav-3 levels
as well. It is conceivable that the ·NO synthesized in
a LPS/IFN-g -treated muscle cell affects both the
same cell and the neighboring cells in an autocrine
and paracrine fashion, decreasing their cav-3 levels.
Significantly, no attenuation in the cav-3 protein
levels was observed in the muscle cells of knockout
animals, reinforcing the notion that the NOS2-
generated ·NO is responsible for the cav-3 protein
decrease. This complete lack of effect of the
cytokines in promoting the downregulation of the cav-3 protein
levels in the knockout mice further supports the observations
previously described for C2C12 myotubes.
Changes in cav-1 levels in other cell types
Other cell types respond to inflammatory stimuli by inducing
NOS2 expression and synthesizing ·NO, so we investigated
whether the cav-1 protein levels diminished in these cell types
(Fig. 8). Liver cells isolated from mice injected with LPS/IFN-
g reduce their cav-1 protein levels significantly (Fig. 8), in
parallel to the results obtained with the cultured C2C12
myotubes. The general downregulation of cav-1 in tissues that
express NOS2 upon inflammation is strengthened by the results
obtained for HepG2 cells and Raw 264.7 macrophages. In
both cases, the endogenous cav-1 protein levels become
downregulated in the presence of LPS/IFN-g , hence reinforcing
our previous findings. The cav-1 protein levels were almost
undetectable in HepG2 cells at 32 hours after treatment whereas
in Raw 264.7 macrophages (despite the low levels observed
under basal conditions) no cav-1 band could be observed after
20 hours of treatment with the cytokines (Fig. 8).
Discussion
In this work, we describe the inhibitory association between
NOS2 and caveolin in cell types that respond to
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Fig. 5. Association of the three caveolin isoforms to NOS2
purified and immunoprecipitated from mouse C2C12
myotubes. Separation of the total lysate of LPS/IFN- g -
treated C2C12 myotubes into a soluble [Supernatant
(Sup.)] or particulate [Pellet (Pel.)] fraction and analysis of
the NOS2, cav-1, cav-2 and cav-3 distribution as judged
by immunodetection (A). Additionally, NOS2 was
immunoprecipitated from C2C12 myotubes treated with
LPS/IFN- g and the association with CaM, cav-1, cav-2 and
cav-3 was determined (B). Finally, NOS2 was affinity
purified using an ADP/Sepharose column (C). In this
experiment, a lane was loaded with the amount of total cell
lysate (Lys.) to give a similar NOS2 immunoreactivity to
that of the purified sample (Pur.). Under this circumstance,
the amount of cav-1, cav-2 and cav-3 that was retained
bound to the purified NOS2 was compared with that
present in the total lysate as determined by immunoblot
(C).
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proinflammatory stimuli alongside the downregulation of
caveolin that parallels the transcriptional induction of NOS2.
The protein levels of cav-1, cav-2 and cav-3 all decreased
significantly after the treatment of muscle cells with LPS/IFN-
g . Whereas, cav-1 and cav-2 become downregulated in
response to the cocktail of bacterial LPS and cytokine, cav-3
responded to the NOS2-derived ·NO itself and became
degraded/repressed. In fact, incubation of the C2C12 myotubes
with the ·NO donor DETA-NONOate triggered the decline in
the cav-3 protein levels without affecting cav-1 and cav-2,
suggesting a specific effect on this caveolin isoform.
Fig. 6. Synthesis of ·NO in mouse C2C12 myotubes treated with
LPS/IFN- g when incubated with antisense phosphorothioates (ASP)
of cav-1, cav-2 and cav-3 (A), and abrogation of caveolin-1
downregulation by protein kinase inhibitors (B). C2C12 myotubes
were treated for 8 hours with antisense phosphorothioate
oligonucleotides complementary to the first 21 bases of the mRNA
encoding cav-1, cav-2 and cav-3. After the treatment, the muscle
cells were challenged with LPS/IFN-g for 36 hours and the amount
of ·NO that accumulates was determined with the Griess assay. The
antisense oligonucleotides (ASP) were added individually (cav-1,
cav-2 and cav-3) or in combination (cav-123). A scrambled oligo
corresponding to the cav-1 base sequence was also used as a control.
The absence of changes in NOS2 and b -tubulin in each case is
confirmed by immunodetection (A, bottom). The results shown are
representative of ten individual experiments. In order to determine
the pathway of downregulation followed by cav-1 and cav-2 in the
presence of the LPS/IFN-g mixture, the cells were incubated with
various protein kinase inhibitors for 48 hours (B). Subsequently, the
levels of cav-1 were determined by immunodetection. The
concentration of nitrites in the supernatant in the presence of 10 m M
Erk inhibitor PD was also determined (right). *P<0.001 vs the
LPS/IFN- g condition. Error bars represent deviation from the
average.
Fig. 7. Changes induced in NOS2, cav-1 and cav-3 levels in muscle
(quadriceps) of wild-type (NOS2+/+) and knock-out (NOS2–/–) mice
upon treatment with LPS/IFN-g . The LPS/IFN-g proinflammatory
stimulus was maintained in animals for 36 hours and the muscular
tissue was processed. The intensity of each immunodetected protein
band was quantified using the UVI-band software and represented as
a vertical bar chart. The results shown are representative of two
individual experiments, with four mice used in each condition tested.
Fig. 8. Changes in the cav-1 levels observed with the LPS/IFN- g
proinflammatory stimulus in mouse hepatocytes, HepG2 cells and
Raw 264.7 macrophages. Mice were injected with LPS (1.5 m g LPS
g–1) and IFN-g (8 U g–1), and the changes in the cav-1 levels were
determined by immunodetection. HepG2 and Raw 264.7 were grown
and challenged with the proinflammatory stimuli.
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We have demonstrated that, within skeletal muscle C2C12
myocytes, a membrane-associated subpopulation of NOS2 is
present in direct contact with caveolin. This particulate NOS2
associates with both the sarcolemma (plasma membrane) of the
myotubes and with intracellular membranes. Both skeletal
muscle and the myotubes differentiated from the mouse C2C12
cell line are known to possess cav-1, cav-2 and cav-3 (Gath et
al., 1999; Tang et al., 1996; Scherer et al., 1997; Song et al.,
1996), and express NOS2 in abundance when challenged with
LPS/IFN- g (Williams et al., 1994; Stamler et al., 2001). We
have immunoprecipitated and purified NOS2 from C2C12
myotubes, providing evidence of its association with
calmodulin and with cav-1, and more marginally with cav-2
and cav-3. In addition, although the LPS/IFN- g treatment led
to a drop in the cav-1 protein levels, a significant amount
of the remaining cellular cav-1 associate with NOS2.
Interestingly, the major cellular path of NOS2 degradation
is the 26S proteasome (Musial et al., 2001), and cav-1
overexpression has been reported to promote the degradation
of NOS2 via the proteasome in human colon carcinoma cells
(Felley-Bosco et al., 2000). Because the addition of peptides
corresponding to the ‘scaffolding domain’ of cav-1 to purified
NOS2 has been reported to abrogate its enzymatic activity
(García-Cardena et al., 1997), the association between NOS2
and cav-1 that we observed in muscular tissues could reflect an
inactive protein on its route towards proteasomal degradation.
It remains to be established, therefore, which post-translational
modifications give NOS2 the ability to associate with caveolar
membranes. Interestingly, the NOS2 present in muscle cells
migrated with a slightly higher molecular mass than its soluble
counterpart. This piece of data is in accordance with the results
obtained by Nathan and co-workers when working with
macrophage NOS2 (Vodovotz et al., 1995), strongly implying
that certain post-translational modifications that increase the
total mass of NOS2 might be responsible for its targeting to
membranes.
We report here that the association of NOS2 to cav-1 and,
more marginally, to cav-2 and cav-3 impeded ·NO synthesis,
as inferred from the augmented level of ·NO detected
upon incubation with cav-1, cav-2 and cav-3 antisense
phosphorothioate oligonucleotides. The comparable increase
in ·NO synthesis that we observed for cav-1 and cav-2
antisense phosphorothioates, despite the fact that very little
cav-2 protein is associated with immunoprecipitated and
purified NOS2, very likely reflects the physical and functional
interactions existing between cav-1 and cav-2 (Smart et al.,
1999).
Additionally, we have shown that NOS2, which unlike
endothelial NOS3 is known to bind irreversibly to calmodulin,
associates with cav-1, cav-2 and cav-3, and becomes
inactivated without releasing the CaM molecule. Therefore,
the synthesis of ·NO achieved by both isoforms of NOS
become modulated differently regarding their CaM-caveolin
association.
The inability of NOS2 knockout but not wild-type mice to
downregulate their cav-3 levels clearly indicates that nitric
oxide exerts a specific transcriptional or transductional
regulation of the cav-3 protein levels in muscular cells. A
precedent for this is provided by experiments in which
transient transfection of muscle cells with myogenin, a helix-
loop-helix transcription factor, activated cav-3 reporter gene
expression, whereas Id2 overexpression inhibited cav-3
promoter activation by myogenin (Biederer et al., 2000). Our
data suggest that nitric oxide might interfere with certain
myogenic basic helix-loop-helix transcription factors such as
myogenin, MyoD, Myf5 and MRF4. However, cardiomyocytes
have a well documented interaction of cav-3 and endothelial
NOS3, providing a precedent for the downregulation of the
cav-3 levels. In rabbits raised under hypoxic conditions for 9
days, the myocardium responds increasing the amount of
NOS3 and approximately halves the cellular levels of cav-3
(Shi et al., 2000).
By contrast, the diminution observed for cav-1 and cav-2 in
C2C12 myotubes as a result of the addition of LPS/IFN- g must
be interpreted in terms of a signaling event resulting from the
binding of these agents to their receptors. Regarding the
downregulation of cav-1 in response to LPS/IFN- g challenge,
previous work has shown that activation of p42/p44 Erk and
non-receptor tyrosine kinases such as Src and Abl are sufficient
to accomplish this effect (Smart et al., 1999; Engelman et al.,
1999). Indeed, a selective inhibitor of Erk activation impaired
cav-1 and cav-2 loss under these conditions. Additionally, the
close proximity of the cav-1 and cav-2 genes in mouse and
humans (Fra et al., 2000), together with the observation that
cav-2 is co-expressed with cav-1 in many tissues, forming
hetero-oligomers, has lead to the proposal of their
transcriptional co-regulation (Scherer et al., 1997; Smart et al.,
1999; Fra et al., 2000). In this context, it must be noted that
prolactin has been observed to regulate cav-1 gene expression
negatively in the mammary gland during lactation via a Ras-
dependent mechanism, and, interestingly, the prolactin
receptor is a cytokine receptor (Park et al., 2001).
In addition, our data indicate that the downregulation of the
cellular cav-1 levels in the presence of LPS/IFN-g might be a
general phenomenon because, rather than being a unique
feature of C2C12 myotubes, it is shared by other cell types, in
agreement with the results reported by Lei and Morrison (Lei
and Morrison, 2000).
Finally, a consideration should be made regarding the
relative levels of NOS2 and caveolin in a particular cell. The
results reported in this work, in addition to the description of
the opposite regulation between NOS2 and caveolins, might be
relevant to understand the fine tuning of NOS activity in those
situations in which a moderate expression of NOS2 occurs,
offering to the cell the possibility of selectively regulate and
re-distribute, perhaps in specific microdomains, the local
synthesis of ·NO. This subcellular targeting and localization of
NOS2 might be responsible for its activation state, because
both cav-1 and the muscle-specific cav-3 isoform are
predominantly associated to the sarcolemma. This situation
might be of interest in those cases in which ·NO is mainly
involved in signaling and not in other functions that require a
high-output production. Unraveling the biological effects of
caveolin-targeted NOS2 subcellular localization might provide
new insights into the broad spectrum on NOS2 inducibility
among cells, distinct from those directly involved in host
defense.
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